**Study Summary** This study is testing a new drug called TORL-1-23 for people with advanced ovarian cancer, which is a type of cancer in a woman's ovaries. The study is in Phase 2, which means it’s checking how safe the drug is and how well it works. The study is looking for women who are at least 18 years old and have a specific type of cancer that hasn’t responded to platinum-based treatments, a common type of cancer therapy. Participants should not have more than three previous cancer treatments. The study requires specific health conditions, like having enough healthy blood cells and organs that work well. Those with certain other health issues or types of cancer cannot join the study. **Key Points:** - Participants will be monitored for safety and effectiveness of TORL-1-23. - Participants must not have received certain treatments recently before starting the study. - Participants should not have other serious health problems or the study may pose a risk. For interested participants, it's important to have a detailed discussion with the doctors to understand all requirements and potential risks involved.